Ropes & Gray advised GHO Capital Partners LLP (“GHO”), a European specialist investor in global healthcare, in a business combination agreement between two contract development and manufacturing organizations (CDMOs), RoslinCT and Lykan Bioscience.
Earlier in 2022, GHO investment in RoslinCT, a cell and gene therapy CDMO based in Edinburg. As part of the agreement, GHO is making a majority investment in Lykan, a CDMO focused on cell-based therapies based in Massachusetts, and is backing the funding of the combined entity. The transatlantic merger will benefit from expanded capacity, with process and analytical development laboratories and cGMP manufacturing facilities in two countries.
The combined group will also offer process development expertise and cGMP manufacturing for a range of autologous and allogeneic cell therapies, with expertise in gene editing and induced pluripotent stem cell (iPSC) capabilities.
The Ropes & Gray team that advised GHO Capital Partners LLP (“GHO”), included private equity partners Neill Jakobe and Tim Castelli, tax, employment & benefits partners Elaine Murphy and Jen Cormier, health care partner Christina Bergeron, real estate partner Peter Alpert, life sciences regulatory & compliance partner Joshua Oyster, IP transactions counsel Thomas Burke, and private equity associate Raxit Shah.